MEDI 447 |
| The management of cardiac arrhythmias is primarily concerned with restoring and maintaining sinus rhythm and preventing symptomatic and/or life-threatening arrhythmias. Cardiac arrhythmias are disorders of rate, rhythm, impulse generation or conduction that are driven by underlying cardiovascular disease. Currently available antiarrhythmic drugs have limited efficacy, documented risk of proarrhythmia and side effect profiles that limit tolerability. Over the last 15 years, antiarrhythmic drug use has declined and registrations of new chemical entities have literally come to a standstill. New advances in antiarrhythmic drug development are now focused on creating chemical entities with desired profiles of action and selectivity. Emerging therapeutic compounds hold the promise of superior efficacy and tissue selectivity with reduced potential for cardiac depression and proarrhythmia. Challenges in the regulatory environment and the burden of past failures make this therapeutic area difficult, but the growing unmet medical need makes it imperative to identify superior antiarrhythmic drugs. The goal of this symposium is to provide an overview of the emerging molecular targets that are being pursued in drug development today. |
|
Antiarrhythmic Agents
9:00 AM-12:00 PM, Thursday, August 23, 2007 BCEC -- 210A, Oral
Division of Medicinal Chemistry |